BlackRock Future Health ETF
Data updated: 2026-09-25
C000221226 — BlackRock Future Health ETF. United States Multi-Cap / All-Cap Growth Health Care Equity. Holdings, fees, performance and SEC filings.
C000221226 Fund Overview
BlackRock Future Health ETF is a US ETF managed by BlackRock ETF Trust, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: BlackRock ETF Trust
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $11.15M
- 1-year return: 15.4%
- SEC CIK: 0001761055
- SEC series ID: S000069260
- Share class ID: C000221226
C000221226 Investment Objective and Strategy
BlackRock Future Health ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by BlackRock ETF Trust.
Investment objective
The iShares Health Innovation Active ETF (the Fund) seeks to maximize total return.
Principal investment strategy
Under normal market conditions, the Fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. Investments in derivatives are counted toward the Funds 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one or more market risk factors associated with such securities. The Fund seeks to invest in innovative and emerging companies in health sciences. The Fund will consider a company to be principally engaged in the health sciences group of industries if (i) it is classified in an industry within the health sciences group of industries by a third-party industry classification system or (ii) it is not classified in any industry by such third-party industry classification system and BFA determines that the company is principally engaged in the health sciences group of industries.
Companies in the health sciences group of industries include healthcare providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or financial support. Other companies in the health sciences group of industries in which the Fund may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences.
The Fund will concentrate its investments in the health sciences group of industries. While the Fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences companies include those engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance; improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health. The Fund may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets.
The Fund will focus its investments in mid- and small-capitalization companies. Foreign securities in which the Fund may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated. The Fund invests primarily in equity securities, including common stocks, preferred stocks, warrants and depository receipts, of health sciences companies and equity interests in real estate investment trusts (REITs) that own hospitals. The Fund may invest in shares of companies through initial public offerings (IPOs). The Fund may also purchase convertible securities. The Fund may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter (OTC) put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques (collectively, Strategic Transactions).
The Fund may engage in Strategic Transactions for duration management and other risk management purposes, including to attempt to protect against possible changes in the market value of the Funds portfolio resulting from trends in the securities markets and changes in interest rates or to protect the Funds unrealized gains in the value of its portfolio securities, to facilitate the sale of portfolio securities for investment purposes, to establish a position in the securities markets as a temporary substitute for purchasing particular securities or to enhance income or gain. The Fund may invest up to 20% of its net assets plus any borrowings for investment purposes in other investments, including equity securities issued by companies that are not principally engaged in the health sciences group of industries and debt securities issued by any issuer, including non-investment grade debt securities.
The Funds investments in non-investment grade securities and those deemed by Fund management to be of similar quality are considered speculative with respect to the issuers capacity to pay interest and repay principal and are commonly referred to as junk or high yield securities.
C000221226 Holdings
Top 10 holdings of BlackRock Future Health ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Merck & Co Inc | 5.91% |
| Gilead Sciences Inc | 4.86% |
| Johnson & Johnson | 4.49% |
| Edwards Lifesciences Corp | 4.42% |
| Thermo Fisher Scientific Inc | 4.18% |
| Charles River Laboratories International Inc | 3.72% |
| Blackrock Cash Funds Treasury Sl Agency Shares | 3.68% |
| Danaher Corp | 3.63% |
| Biogen Inc | 3.52% |
| Waters Corp | 3.50% |
C000221226 Portfolio Allocation
Asset-class allocation of BlackRock Future Health ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 95.6% |
| Cash & Equivalents | 5.5% |
C000221226 Performance
Total returns for C000221226 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -7.4% |
| 1 year | 15.4% |
| 3 years (annualised) | 4.9% |
| 5 years (annualised) | -1.2% |
C000221226 Risk Information
Risk metrics for C000221226, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.1%
C000221226 Costs and Fees
C000221226 costs about $55 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.55%
- Gross expense ratio: 0.77%
- Portfolio turnover: 109%
- Brokerage commissions: 3.91 bps of average net assets (SEC N-CEN)
C000221226 Cashflows
Over the 12 months to 2026-04, BlackRock Future Health ETF had net inflows of $7.09M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $0 |
| 2026-03 | $0 |
| 2026-02 | $1.23M |
| 2026-01 | $2.52M |
| 2025-12 | $1.24M |
| 2025-11 | $0 |
C000221226 Debt Constituents
No individual debt constituents are reported in BlackRock Future Health ETF's latest SEC N-PORT filing.
C000221226 Prospectus and SEC Filings
Official BlackRock Future Health ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-11-21
- Prospectus (485BPOS) — filed 2024-11-22
- Prospectus supplement (497) — filed 2024-10-10
- Portfolio holdings (N-PORT) — filed 2026-09-25
- Portfolio holdings (N-PORT) — filed 2026-06-25
- Portfolio holdings (N-PORT) — filed 2026-03-26
- Annual census (N-CEN) — filed 2025-10-14
- Annual census (N-CEN) — filed 2024-10-15
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.